Related Experiment Video
Updated: May 19, 2026
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
Published on: October 3, 2010
Medulloblastoma in adults. Treatment outcome, relapse patterns, and prognostic factors
1Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Background And Purpose:
In this study, the clinical outcome and prognostic factors of adult medulloblastoma patients receiving multimodal treatment were investigated.
Patients And Methods:
The clinical manifestations, treatment variables, and outcome of adult patients with medulloblastoma at our institution between 1983 and 2009 were retrospectively reviewed.
Results:
A total of 20 adult patients were included (median age 22 years). Craniospinal irradiation (CSI) was given postoperatively. The craniospinal axis received a median of 30 Gy (range 23.4-39.6 Gy) in fractions of 1.6-2 Gy/day, and the tumor was boosted to a total median dose of 50 Gy (range 50-55.25 Gy). The 3-year disease-free survival (DFS) and overall survival (OS) rates for all patients were 45% and 50%, respectively. In univariate analysis, Karnofsky Performance Scale (KPS) > 70, neurologic symptoms duration > 30 days, lateral tumor location, standard risk patients, no hydrocephalus, radiotherapy (RT) treatment field (CSI + brain boost), and CSI dose ≥ 30 Gy were associated with better DFS. Standard-risk patients, RT treatment field (CSI + brain boost), and CSI dose ≥ 30 Gy were also significantly associated with better OS.
Conclusion:
The combined modality treatment results in a favorable outcome for adult medulloblastoma patients. Further investigation of the prognostic factors, radiation-related factors, and systemic chemotherapy is needed.
Insights
Multimodal treatment offers a favorable outcome for adult medulloblastoma patients. Key prognostic factors include performance status and radiation therapy details, guiding future research in this rare adult cancer.
Area of Science:
- Neuro-oncology
- Radiation Oncology
- Clinical Outcomes Research
Background:
- Medulloblastoma is rare in adults, with outcomes often differing from pediatric cases.
- Multimodal treatment is standard, but prognostic factors in adults require clarification.
Purpose of the Study:
- To investigate the clinical outcomes of adult medulloblastoma patients.
- To identify prognostic factors influencing survival in this population.
Main Methods:
- Retrospective review of 20 adult medulloblastoma patients (1983-2009).
- Analysis of clinical data, treatment variables (including craniospinal irradiation doses), and patient outcomes.
- Univariate analysis to identify significant prognostic factors.
Main Results:
- 3-year disease-free survival (DFS) and overall survival (OS) were 45% and 50%, respectively.
- Favorable prognostic factors for DFS included Karnofsky Performance Scale > 70, symptom duration > 30 days, lateral tumor location, standard risk, no hydrocephalus, craniospinal irradiation (CSI) + brain boost, and CSI dose ≥ 30 Gy.
- Standard risk, CSI + brain boost, and CSI dose ≥ 30 Gy were associated with better OS.
Conclusions:
- Combined modality treatment yields favorable outcomes for adult medulloblastoma.
- Further research is needed on prognostic factors, radiation parameters, and chemotherapy efficacy.
